Abstract:Aneuploidy, including the gain or loss of whole chromosomes or chromosome arms, is a near-universal feature of cancer. We previously applied methods that define chromosome arm aneuploidy to over 10,000 tumors in the Cancer Genome Atlas (TCGA). Cancer subtypes are often characterized by tumor specific patterns of chromosome arm copy number alterations and breakpoints; for example, squamous cell carcinomas (SCCs) from different tissues of origin are characterized by chromosome 3p (chr3p) loss and chromosome 3q (chr3q) gain. From the TCGA aneuploidy data, we developed an algorithm called BISCUT to distinguish peak regions of aneuploidy breakpoints on each chromosome arm. BISCUT identified loci affected by broad copy number alterations that provide fitness advantages or disadvantages both within individual cancer types and across cancers. Our analyses are consistent with selection being the primary driver of aneuploidy events in cancer. We next wanted to validate some BISCUT peaks without a known driver, to identify potential gene deletions that are beneficial in cancer cells. We focused on chromosome 8p (chr8p), as this arm is frequently deleted across cancer types, but no strong tumor suppressors have been identified. Recent advances in genome engineering allow generation of large chromosomal alterations and validation of findings from patient genomic data. For this study, we used our CRISPR-Cas9 arm-deletion system to delete chr8p in human immortalized epithelial cells. Cells with chr8p deletion showed lower amounts of cell death in culture. Knockdown of WRN, one of the two genes in the smallest chr8p BISCUT peak, was sufficient to reproduce this phenotype, suggesting that WRN haploinsufficiency may be beneficial to tumor development. As aneuploidy occurs in tissue-specific patterns, we also wanted to explore the role of chr3 arm aneuploidies in squamous cancers. We again used the CRISPR-Cas9 system to delete one copy of chr3p in a human immortalized lung epithelial cell line similar to the putative cell-of-origin in lung SCC. Consistent with patient data, expression of chr3p genes was decreased upon deletion, as well as increased expression of interferon response genes. Cells with chr3p deletion initially proliferated more slowly than their siblings. Interestingly, after several passages in culture, this proliferation defect was rescued in chr3p deleted cells. Genome sequencing and karyotype analyses suggested that this was partially the result of chr3 duplication, with cells transitioning to a state of chr3q gain. Culturing these cells as organoids also demonstrated that chr3p deletion and chr3q gain can affect basal cell differentiation, consistent with their high frequency in squamous cancers. Our genome engineering approach to model chromosome arm aneuploidies provides a robust model to validate drivers from aneuploidy events, which will be critical to address the gap in our understanding of aneuploidy in cancer. In addition, our methods have identified consequences of individual aneuploidy events, which will lead to new precision oncology targets for patients. Citation Format: Alison M. Taylor. Functional and computational approaches to uncover selection advantages of cancer aneuploidy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl) nr NG03.

Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy

Aneuploid serves as a prognostic marker and favors immunosuppressive microenvironment in ovarian cancer

DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load

Aneuploidy in neoplasia: Single‐cell data on 83,862 tumors

67 Cancer aneuploidy is associated with a distinct tumor immune microenvironment and impacts outcomes to immune checkpoint inhibition in nonsquamous non-small cell lung cancer

The Unfolded Protein Response at the Tumor-Immune Interface

Proteogenomic analysis reveals adaptive strategies to alleviate the consequences of aneuploidy in cancer

Solving the chromosome puzzle of aneuploidy in cancer

An aneuploidy epistasis map reveals metabolic vulnerabilities associated with supernumerary chromosomes in cancer

Interplay between DNA damage repair and apoptosis shapes cancer evolution through aneuploidy and microsatellite instability

Oncogene-like addiction to aneuploidy in human cancers

Abstract NG03: Functional and computational approaches to uncover selection advantages of cancer aneuploidy

Aneuploidy as a driver of human cancer

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

Increased RNA and protein degradation is required for counteracting transcriptional burden and proteotoxic stress in human aneuploid cells

Abstract 413: Aneuploid cells depend on the RAF/MEK/ERK pathway and on RNA degradation for overcoming DNA damage and transcriptional burden

Human aneuploid cells depend on the RAF/MEK/ERK pathway for overcoming increased DNA damage

Abstract 5641: Tumor cell intrinsic factors in colorectal cancer immune evasion

Frequency-dependent selection of neoantigens fosters tumor immune escape and predicts immunotherapy response

Abstract B021: Aneuploidy-associated cohesin RAD21 gains promote immune evasion in prostate cancers

Aneuploidy theory explains tumor formation, the absence of immune surveillance, and the failure of chemotherapy